Mesenchymal stem cells for the treatment of neurodegenerative disease
- 17 November 2010
- journal article
- review article
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 5 (6) , 933-946
Abstract
Mesenchymal stem cells/marrow stromal cells (MSCs) present a promising tool for cell therapy, and are currently being tested in US FDA-approved clinical trials for myocardial infarction, stroke, meniscus injury, limb ischemia, graft-versus-host disease and autoimmune disorders. They have been extensively tested and proven effective in preclinical studies for these and many other disorders. There is currently a great deal of interest in the use of MSCs to treat neurodegenerative diseases, in particular for those that are fatal and difficult to treat, such as Huntington’s disease and amyotrophic lateral sclerosis. Proposed regenerative approaches to neurological diseases using MSCs include cell therapies in which cells are delivered via intracerebral or intrathecal injection. Upon transplantation into the brain, MSCs promote endogenous neuronal growth, decrease apoptosis, reduce levels of free radicals, encourage synaptic connection from damaged neurons and regulate inflammation, primarily through paracrine...Keywords
Funding Information
- California Institute for Regenerative Medicine (TR1–01257)
- CIRM Training
- IH NHLBI (1RO1 HL073256–01)
- IH NHLBI (5P30AG010129–19)
This publication has 120 references indexed in Scilit:
- Huntingtin-associated Protein-1 Interacts with Pro-brain-derived Neurotrophic Factor and Mediates Its Transport and ReleaseJournal of Biological Chemistry, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial InfarctionJACC, 2009
- Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease MiceMolecular Therapy, 2009
- A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interferenceExperimental Neurology, 2009
- Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease PatientsCurrent Biology, 2009
- Stem cell‐based cell therapy in neurological diseases: A reviewJournal of Neuroscience Research, 2009
- Trophic factors therapy in Parkinson's disease2009
- Direct Muscle Delivery of GDNF With Human Mesenchymal Stem Cells Improves Motor Neuron Survival and Function in a Rat Model of Familial ALSMolecular Therapy, 2008
- In Vivo Biosafety Model to Assess the Risk of Adverse Events From Retroviral and Lentiviral VectorsMolecular Therapy, 2008
- Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficitsProceedings of the National Academy of Sciences, 2007